Coya Therapeutics (NASDAQ: COYA) — Perfil da empresa, notícias e dados financeiros
Coya Therapeutics develops innovative therapies targeting autoimmune and neurodegenerative diseases using Treg technology.

Coya Therapeutics
Coya Therapeutics (NASDAQ:COYA) focuses on developing innovative therapies aimed at combating a wide range of autoimmune, neurodegenerative, and aging-related diseases. By harnessing the power of regulatory T cells (Tregs) and leveraging advanced biotechnological processes, Coya Therapeutics aims to pave new pathways in the treatment of conditions like ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, and systemic lupus erythematosus (SLE). Central to their mission is the commitment to advancing clinical research, with several key projects in various stages of development aimed at unlocking the therapeutic potential of Tregs. Their objectives include not only advancing the science behind autoimmune and neurodegenerative disease treatments but also improving the quality of life for patients suffering from these challenging conditions.
Resumo
Operações
Produtos e/ou serviços de Coya Therapeutics
- Development of therapeutic treatments focused on neurodegenerative diseases such as ALS and Alzheimer's.
- Research on anti-inflammatory therapeutics for autoimmune disorders.
- Innovative approaches to enhancing the bioavailability of treatments for better patient outcomes.
- Collaborations with academic institutions for advanced research in neurology and immunology.
- Engagement in clinical trials to validate the efficacy and safety of new drugs and therapies.
- Leveraging proprietary technology platforms to discover novel therapeutic targets.
equipe executiva do Coya Therapeutics
- Arun SwaminathanCEO & Director
- Fred GrossmanPresident & Chief Medical Officer
- David S. SnyderCFO & COO
- Aaron ThomeHead of Neuroinflammation Platform
- Michelle FrazierSenior Vice President of Regulatory
- Karen KingSenior VP of Program Management & Clinical Operations
Últimas notícias sobre a Coya Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Coya Therapeutics , em USD.
- Cap. de mercado
- 95,2 mi
- Receita (TTM)
- 8 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- -270.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,9 mi | -20,3 mi | -21,2 mi | |
| 3,6 mi | -17,2 mi | -14,9 mi | |
| 6 mi | -7,9 mi | -8 mi | |
| 0 | -9,8 mi | -12,2 mi |